Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease

Boncoraglio, Giorgio B.; Bodini, Antonella; Brambilla, Carla; Corsini, Elena; Carriero, Maria R.; Parati, Eugenio A.

doi:10.1016/j.clineuro.2008.11.001

« Previous Next »Clinical Neurology and Neurosurgery
Volume 111, Issue 3 , Pages 270-273, April 2009

Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease

Giorgio B. Boncoraglio
- Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano, Italy
- Corresponding author. Tel.: +39 02 2394 2385; fax: +39 02 70638217.
Antonella Bodini
- Consiglio Nazionale delle Ricerche, Istituto di Matematica Applicata e Tecnologie Informatiche, Milano, Italy
Carla Brambilla
- Consiglio Nazionale delle Ricerche, Istituto di Matematica Applicata e Tecnologie Informatiche, Milano, Italy
Elena Corsini
- Laboratory of Clinical Investigations, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy
Maria R. Carriero
- Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano, Italy
Eugenio A. Parati
- Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano, Italy

Received 28 April 2008; received in revised form 6 September 2008; accepted 2 November 2008.

Abstract

Objective

Evidence is growing that some patients are not responsive to the antithrombotic action of aspirin. We prospectively evaluated the ability of aspirin resistance status, determined by PFA-100, to predict new thrombotic events in patients with stable ischemic cerebrovascular disease.

Methods

We studied 129 consecutive patients with stroke, transient ischemic attack (TIA) or vascular cognitive impairment. We assessed relationships between aspirin resistance, risk factors for ischemic cerebrovascular disease, and occurrence of new thrombotic events (composite of stroke, TIA, myocardial infarction, and cardiovascular death).

Results

Aspirin resistance, found in 26 (20.1%) cases, was unrelated to any of the examined vascular risk factors. During mean follow-up of 56 months, new thrombotic events occurred in 19 patients (14.7%), four with aspirin resistance (15.4%) and 15 (14.6%) without aspirin resistance (p=1.00).